Hostname: page-component-6bf8c574d5-w79xw Total loading time: 0 Render date: 2025-02-23T08:58:09.470Z Has data issue: false hasContentIssue false
  • English
  • Français

Extended-Spectrum β-Lactamase Producers Reported as Susceptible to Piperacillin-Tazobactam, Cefepime, and Cefuroxime in the Era of Lowered Breakpoints and No Confirmatory Tests

Published online by Cambridge University Press:  02 January 2015

Dror Marchaim ,
Bharath Sunkara ,
Paul R. Lephart ,
Uma Mahesh Gudur ,
Ashish Bhargava ,
Ryan P. Mynatt ,
Jing J. Zhao ,
Suchitha Bheemreddy ,
Kayoko Hayakawa  and
Teena Chopra
...Show all authors
Dror Marchaim*
Affiliation:
Division of Infectious Diseases, Detroit Medical Center, Wayne State University, Detroit, Michigan
Bharath Sunkara
Affiliation:
Division of Infectious Diseases, Detroit Medical Center, Wayne State University, Detroit, Michigan
Paul R. Lephart
Affiliation:
Division of Infectious Diseases, Detroit Medical Center, Wayne State University, Detroit, Michigan
Uma Mahesh Gudur
Affiliation:
Division of Infectious Diseases, Detroit Medical Center, Wayne State University, Detroit, Michigan
Ashish Bhargava
Affiliation:
Division of Infectious Diseases, Detroit Medical Center, Wayne State University, Detroit, Michigan
Ryan P. Mynatt
Affiliation:
Division of Infectious Diseases, Detroit Medical Center, Wayne State University, Detroit, Michigan
Jing J. Zhao
Affiliation:
Division of Infectious Diseases, Detroit Medical Center, Wayne State University, Detroit, Michigan
Suchitha Bheemreddy
Affiliation:
Division of Infectious Diseases, Detroit Medical Center, Wayne State University, Detroit, Michigan
Kayoko Hayakawa
Affiliation:
Division of Infectious Diseases, Detroit Medical Center, Wayne State University, Detroit, Michigan
Teena Chopra
Affiliation:
Division of Infectious Diseases, Detroit Medical Center, Wayne State University, Detroit, Michigan
Sorabh Dhar
Affiliation:
Division of Infectious Diseases, Detroit Medical Center, Wayne State University, Detroit, Michigan
Keith S. Kaye
Affiliation:
Division of Infectious Diseases, Detroit Medical Center, Wayne State University, Detroit, Michigan
*
Division of Infectious Diseases, 5 Hudson, Harper University Hospital, 3990 John R. Street, Detroit, MI 48201 (drormc@hotmail.com)
Rights & Permissions [Opens in a new window]

Abstract

An abstract is not available for this content so a preview has been provided. As you have access to this content, a full PDF is available via the ‘Save PDF’ action button.
Image of the first page of this content. For PDF version, please use the ‘Save PDF’ preceeding this image.'
Type
Research Brief
Information
Infection Control & Hospital Epidemiology , Volume 33 , Issue 8 , August 2012 , pp. 853 - 855
Copyright
Copyright © The Society for Healthcare Epidemiology of America 2012

References

1.Schwaber, MJ, Carmeli, Y. Mortality and delay in effective therapy associated with extended-spectrum β-lactamase production in Enterobacteriaceae bacteraemia: a systematic review and metaanalysis. J Antimicrob Chemother 2007;60(5): 913–920.Google Scholar
2.Clinical and Laboratory Standards Institute (CLSI). Performance Standards for Antimicrobial Susceptibility Testing: Nineteenth Informational Supplement. Approved standard M100-S19. Wayne, PA: CLSI, 2009.Google Scholar
3.Paterson, DL, Ko, WC, Von Gottberg, A, et al. Antibiotic therapy for Klebsiella pneumoniae bacteremia: implications of production of extended-spectrum ß-lactamases. Clin Infect Dis 2004;39(1):31–37.Google Scholar
4.Paterson, DL, Bonomo, RA. Extended-spectrum β-lactamases: a clinical update. Clin Microbiol Rev 2005;18(4): 657–686.CrossRefGoogle ScholarPubMed
5.Rodriguez-Bano, J, Navarro, MD, Retamar, P, Picon, E, Pascual, A. β-Lactam/β-lactam inhibitor combinations for the treatment of bacteremia due to extended-spectrum β-lactamase-producing Escherichia coli: a post hoc analysis of prospective cohorts. Clin Infect Dis 2012;54(2): 167–174.Google Scholar
6.Clinical and Laboratory Standards Institute (CLSI). CLSIM100-S20 (2010) Cephalosporin and Aztreonam Breakpoint Revisions Fact Sheet. Wayne, PA: CLSI, 2010.Google Scholar
7.Jenkins, SG. Rationale Supporting CLSI Changes to Interpretive Criteria (Breakpoints) for Several Cephalosporines and Aztreonam When Testing Enterobacteriaceae. Washington, DC: American Society for Microbiology, 2010:1–4.Google Scholar
8.Rodriguez-Bano, J, Picon, E, Navarro, MD, Lopez-Cerero, L, Pascual, A. Impact of changes in CLSI and EUCAST breakpoints for susceptibility in bloodstream infections due to extended-spectrum β-lactamase-producing Escherichia coli. Clin Microbiol Infect doi:10.1111/j.l469-0691.2011.03673.x. Published September 13, 2011.CrossRefGoogle Scholar
9.de Oliveira, KR, de Freitas, AL, Willers, DM, Barth, AL, Zavascki, AP. High frequency of β-lactam susceptibility in CTX-M-type extended-spectrum-β-lactamase-producing Klebsiella pneumoniae, Escherichia coli and Proteus mirabilis according to the new CLSI recommendations. J Antimicrob Chemother 2010;65(11): 2481–2483.Google Scholar
10.Ambrose, PG, Bhavnani, SM, Jones, RN. Pharmacokinetics-pharmacodynamics of cefepime and piperacillin-tazobactam against Escherichia coli and Klebsiella pneumoniae strains producing extended-spectrum β-lactamases: report from the ARREST program. Antimicrob Agents Chemother 2003;47(5): 1643–1646.Google Scholar
11.Perez, F, Bonomo, RA. Can we really use β-lactam/β-lactam inhibitor combinations for the treatment of infections caused by extended-spectrum β-lactamase-producing bacteria? Clin Infect Dis 2012;54(2): 175–177.Google Scholar